Medable is working with fellow Californian company Masimo to bring medical-grade wearable devices to clinical research.

Masimo’s pulse oximeter technology has been trusted by clinicians for over 25 years to monitor more than 200 million patients each year and is now enabling more patients to participate in clinical trials without the burdens of ongoing trips to the trial site for routine testing.

Medable has integrated Masimo’s MightySat Rx pulse oximeter (techdocs.masimo.com/globalassets/techdocs/pdf/lab-9121c_master.pdf) into its evidence-generation platform for eight big-pharma-sponsored clinical trials spanning 25 countries including more than 3000 patients across two oncology indications: lung and breast cancer. The device integration eliminates significant travel burdens from often very sick patients while empowering them to participate in potentially lifesaving clinical trials.

With this partnership, Medable also enables both subjective data capture – via humans through Medable’s eCOA+ (www.medable.com/platform/ecoa-epro) – and objective data capture via Masimo’s connected sensors for multifaceted, deeper data analysis in trials.

“Medable has always been a leader in digital and decentralised clinical trials, so we are excited to work with a forward-thinking organisation with the ambition and ability to transform research,” said Daniel Cantillon, chief medical officer at Masimo (www.masimo.com). “Clinical trials require top-in-class accuracy and data quality both on-site and off-site from clinical offices. Medable is solving this problem through its advocacy and by empowering more patients to participate in research. And, Medable’s flexible platform enables scalability and data aggregation for a holistic approach.”

Medable selected Masimo for its reputation and signal extraction technology (SET) that delivers accurate readings even in difficult conditions, such as patient motion or low perfusion.

“Masimo’s SET pulse oximetry is sensitive enough to capture key vitals on the very ill like cancer patients, plus it works on all skin tones, all ages, and is easy to use,” said Musaddiq Khan, Medable vice president. “The Masimo team is terrific, and we look forward to long-term collaboration so we can leverage more of their novel wearables to improve data quality and enable patients to participate in trials with less burden.”

One fifth of trials leveraging Medable’s evidence generation platform include a wearable device, and 35% of those are in oncology.

Medable has deployed its software-as-a-service platform in more than 300 decentralised and hybrid clinical trials in 60 countries, serving more than one million patients and research participants globally. Results include 200 per cent faster enrolment and 50 per cent cost reductions.

Medable (www.medable.com) is a privately held, venture-backed company headquartered in Palo Alto, California.